Tetragenetics
Cambridge, US · New York corporation · 3 known investors
Find your way into Tetragenetics
29 people in our graph share verified history with the Tetragenetics team — schools, employers, funds. One of them is your warm intro.
Joe Gerberunlockedknows William Gordon III · together at School of Visual Arts (overlapped)
×7knows the team · via School of Visual Arts
×4knows the team · via Tetragenetics Inc.
Biotechnology company with proprietary technology for ion channel antigens in antibody discovery programs.
Founders & leadership
TC
Theodore ClarkCo-founder
WG
William Gordon IIIinFounderWilliam Gordon III holds a PhD from UC Berkeley with doctoral and postdoctoral research experience at Cold Spring Harbor Laboratory, and an MBA in Finance from the University of Pennsylvania Wharton School. He has held executive roles including CEO, CFO, and COO across multiple companies, most recently serving as COO of a medical device company focused on Alzheimer's disease therapeutics.
KO
Kevin O'BrienExecutive
RD
R. Douglas KahnExecutive
MG
Martin GorovskyNamed on SEC filing
Board
RG
Robert GailusBoard director
BM
Ben MachielseBoard director
CT
Christopher TaronBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$3.6M disclosed across 5 rounds · 2015–2020
▶$1MraisedSep 2020 · 13 investors · BiotechnologyRule 506(b)
▶$1MraisedSep 2020 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher TaronDirector
- Ellen BaronDirector
- Kevin O'BrienExecutive Officer
- Peter KienerDirector
- Alison Taunton-RigbyDirector
- Robert GailusDirector
- Theodore ClarkExecutive Officer, Director
- R Douglas KahnExecutive Officer, Director
- Daniel GrauDirector
- Offering amount
- $2M
- Amount sold
- $1M
- Minimum investment
- $10K
- First sale
- Sep 2020
- Incorporated
- Corporation, New York
- Federal exemptions
- 06b
▶$809.8KraisedJul 2018 · 15 investors · BiotechnologyRule 506(b)
▶$809.8KraisedJul 2018 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Theodore ClarkExecutive Officer, Director
- Robert GailusDirector
- Christopher TaronDirector
- Kevin O'BrienExecutive Officer
- Peter KienerDirector
- R Douglas KahnExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $809.8K
- Minimum investment
- $25K
- First sale
- Jun 2018
- Incorporated
- Corporation, New York
- Federal exemptions
- 06b
▶$1.1MraisedMar 2017 · 21 investors · BiotechnologyRule 506(b)
▶$1.1MraisedMar 2017 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin O'BrienExecutive Officer
- Christopher TaronDirector
- Martin GorovskyDirector
- Peter KienerDirector
- Theodore ClarkExecutive Officer, Director
- Robert GailusDirector
- R Douglas KahnExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.1M
- Minimum investment
- $10K
- First sale
- Feb 2017
- Incorporated
- Corporation, New York
- Federal exemptions
- 06b
▶$336KraisedNov 2015 · 8 investors · BiotechnologyRule 506(b)
▶$336KraisedNov 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- R. Douglas KahnExecutive Officer, Director
- Robert GailusDirector
- Martin GorovskyDirector
- Kevin O'BrienExecutive Officer
- Theodore ClarkExecutive Officer, Director
- Ben MachielseDirector
- Christopher TaronDirector
- Offering amount
- $1.5M
- Amount sold
- $336K
- Minimum investment
- $10K
- First sale
- Nov 2015
- Incorporated
- Corporation, New York
- Federal exemptions
- 06b
▶$338.2KraisedMar 2015 · 8 investors · BiotechnologyRule 506(b)
▶$338.2KraisedMar 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin O'BrienExecutive Officer
- Robert GailusDirector
- R. Douglas KahnExecutive Officer, Director
- Martin GorovskyDirector
- Theodore ClarkExecutive Officer, Director
- Ben MachielseDirector
- Christopher TaronDirector
- Offering amount
- $1.5M
- Amount sold
- $338.2K
- Minimum investment
- $10K
- First sale
- Mar 2015
- Incorporated
- Corporation, New York
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Tetragenetics do?
- Biotechnology company with proprietary technology for ion channel antigens in antibody discovery programs.
- Who founded Tetragenetics?
- Tetragenetics was founded by Theodore Clark, William Gordon III.
- Who are Tetragenetics's investors?
- Tetragenetics's investors include Bantam Group, Boston Harbor Angels, NXT Ventures.
- How much funding has Tetragenetics raised?
- Tetragenetics has disclosed $3.6M raised across 5 rounds.
- Where is Tetragenetics headquartered?
- Tetragenetics is headquartered in Cambridge, US.